{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:50:05Z","timestamp":1793969405455,"version":"4.8.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jtho.2026.103693","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T03:48:50Z","timestamp":1774583330000},"page":"103693","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Brief Report: Low Delta-Like Ligand 3 Expression and T-Cell Exhaustion Drive Resistance to Tarlatamab Combined With Anti\u2013Programmed Cell Death Protein 1 in SCLC"],"prefix":"10.1016","volume":"21","author":[{"given":"Akito","family":"Fukuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyo","family":"Fukami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jumpei","family":"Kashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Yatabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4896-5824","authenticated-orcid":false,"given":"Tatsuya","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2026.103693_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jtho.2026.103693_bib2","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.6004\/jnccn.2021.0058","article-title":"Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"19","author":"Ganti","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jtho.2026.103693_bib3","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/jama.2025.0560","article-title":"Small cell lung cancer: a review","volume":"333","author":"Kim","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.jtho.2026.103693_bib4","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1200\/JCO.22.02823","article-title":"Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: an open-label, Phase I study","volume":"41","author":"Paz-Ares","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103693_bib5","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.103693_bib6","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41698-024-00739-y","article-title":"Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms","volume":"8","author":"Serrano","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.jtho.2026.103693_bib7","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.lungcan.2017.11.018","article-title":"Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer","volume":"115","author":"Tanaka","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2026.103693_bib8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103693_bib9","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41392-025-02327-3","article-title":"Revitalizing T cells: breakthroughs and challenges in overcoming T cell exhaustion","volume":"11","author":"Wu","year":"2026","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jtho.2026.103693_bib10","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","article-title":"Clonal replacement of tumor-specific T cells following PD-1 blockade","volume":"25","author":"Yost","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2026.103693_bib11","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086426001462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086426001462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T09:54:17Z","timestamp":1785837257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086426001462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":11,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1556086426001462"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2026.103693","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brief Report: Low Delta-Like Ligand 3 Expression and T-Cell Exhaustion Drive Resistance to Tarlatamab Combined With Anti\u2013Programmed Cell Death Protein 1 in SCLC","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2026.103693","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103693"}}